Sign In

QCDR
QOPI
QOPI Reporting Registry

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Sign In
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia in Adults Unable to Receive Intensive Chemotherapy

Oncology Practice Insider

Related

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
FDA Approves Osimertinib as Adjuvant Therapy for Non-small Cell Lung Cancer with EGFR Mutations
FDA Approves Relugolix for Advanced Prostate Cancer
FDA Alerts

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On October 16, 2020, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA®, AbbVie Inc. and Genentech Inc.) in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. Read more.